Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ILDEFONSO I RODRIGUEZ RIVERA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1861783185
CMS profile
473649
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,398.92

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,323.93 53
Education $74.99 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ILDEFONSO I RODRIGUEZ RIVERA

NPI 1861783185 · CMS profile ID 473649

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861783185?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ILDEFONSO I RODRIGUEZ RIVERA, NPI 1861783185, CMS profile ID 473649. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861783185?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ILDEFONSO I RODRIGUEZ RIVERA, NPI 1861783185, CMS profile ID 473649. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861783185?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ILDEFONSO I RODRIGUEZ RIVERA, NPI 1861783185, CMS profile ID 473649, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861783185?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $1,398.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $24.0202/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078756131 CMS
Lilly USA, LLC $19.0702/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135033564 CMS
Novartis Pharmaceuticals Corporation $24.4701/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087175945 CMS
GENZYME CORPORATION $14.3701/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139913055 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $422.44 18
PY2022 $597.76 22
PY2023 $1,919.93 30
PY2024 $1,398.92 54
PY2025 $1,229.76 40

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $248.88 1
PY2025 Principal investigator $1,323,437.22 105
PY2024 Recipient $53.84 1
PY2024 Principal investigator $1,256,038.97 117
PY2023 Principal investigator $116,817.17 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

106 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 12/30/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235977717
Principal investigator 1 Deciphera Pharmaceuticals Inc. $15,856.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235977131
Principal investigator 1 PFIZER INC. $2,298.51 12/16/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228737989
Principal investigator 1 BeOne Medicines USA, Inc. $122.00 12/15/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190330799
Principal investigator 1 BeOne Medicines Ltd. $12,973.25 12/09/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190335695
Principal investigator 1 BeOne Medicines USA, Inc. $3,375.00 12/09/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190329371
Principal investigator 1 BeOne Medicines USA, Inc. $9,661.00 12/09/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190329373
Recipient Regeneron Pharmaceuticals, Inc. $248.88 12/09/2025 Covered Recipient Physician A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES No dispute reported 06/30/2026 1184121825
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 12/02/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235976852
Principal investigator 1 BeOne Medicines Ltd. $9,544.00 11/28/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190335687
Principal investigator 1 BeOne Medicines Ltd. $4,772.00 11/28/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190335700
Principal investigator 1 BeOne Medicines USA, Inc. $10,528.00 11/28/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327173
Principal investigator 1 PFIZER INC. $4,631.31 11/26/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228730639
Principal investigator 1 Deciphera Pharmaceuticals Inc. $42,112.00 11/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976283
Principal investigator 1 BeOne Medicines Ltd. $6,000.00 11/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190335683
Principal investigator 1 BeOne Medicines Ltd. $297.00 11/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190335690
Principal investigator 1 BeOne Medicines Ltd. $150.00 11/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190335704
Principal investigator 1 BeOne Medicines Ltd. $11,475.85 11/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190335708
Principal investigator 1 BeOne Medicines Ltd. $1,005.00 11/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190335714
Principal investigator 1 PFIZER INC. $9,795.33 11/14/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228738113
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,000.00 11/12/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976009
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,000.00 11/12/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976013
Principal investigator 1 Deciphera Pharmaceuticals Inc. $24,750.00 11/12/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976017
Principal investigator 1 Merck Sharp & Dohme LLC $255,600.00 11/12/2025 Non-covered Recipient Entity
Next Oncology
A Multicenter Phase I,Ib Dose Escalation Study of WTX 124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232932543
Principal investigator 1 PFIZER INC. $12,806.94 11/04/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228728483
Principal investigator 1 PFIZER INC. $29,750.00 11/04/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
A PHASE 1 OPENLABEL STUDY TO INVESTIGATE PF08046876 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228738337
Principal investigator 1 BeOne Medicines USA, Inc. $50,908.00 10/28/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327193
Principal investigator 1 BeOne Medicines USA, Inc. $3,483.00 10/28/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190329375
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,725.00 10/22/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235975595
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,040.00 10/22/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235975619
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 10/18/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235975534
Principal investigator 1 Deciphera Pharmaceuticals Inc. $450.00 10/18/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235975537
Principal investigator 1 PFIZER INC. $20,899.77 10/08/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228742030
Principal investigator 1 Amgen Inc. $113,951.00 10/07/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1246645060
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 10/07/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235975028
Principal investigator 1 BeOne Medicines USA, Inc. $26,142.00 09/30/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327203
Principal investigator 1 BeOne Medicines Ltd. $395.00 09/23/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190340932
Principal investigator 1 BeOne Medicines USA, Inc. $61.00 09/15/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190330815
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 09/09/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235974196
Principal investigator 1 BeOne Medicines USA, Inc. $9,234.00 09/02/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327201
Principal investigator 1 Merck Sharp & Dohme LLC $161.37 08/31/2025 Non-covered Recipient Entity
Next Oncology
A Phase 1 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-4700 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232929235
Principal investigator 1 BeOne Medicines Ltd. $790.00 08/26/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190340942
Principal investigator 1 Deciphera Pharmaceuticals Inc. $315.00 08/15/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235973797
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 08/15/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235973800
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 08/12/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235973626
Principal investigator 1 BeOne Medicines Ltd. $300.00 07/22/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190330821
Principal investigator 1 BeOne Medicines Ltd. $2,475.00 07/22/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190330823
Principal investigator 1 BeOne Medicines Ltd. $395.00 07/22/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190340936
Principal investigator 1 BeOne Medicines USA, Inc. $12,915.00 07/22/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327199
Principal investigator 1 BeOne Medicines USA, Inc. $30,384.00 07/15/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327181
Principal investigator 1 BeOne Medicines USA, Inc. $300.00 07/15/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190330813
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 07/15/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235972992
Principal investigator 1 BeOne Medicines USA, Inc. $5,290.19 07/07/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190330811
Principal investigator 1 BeOne Medicines USA, Inc. $1,976.40 06/24/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190326724
Principal investigator 1 BeOne Medicines USA, Inc. $3,607.00 06/24/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190330807
Principal investigator 1 BeOne Medicines USA, Inc. $183.00 06/24/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190330809
Principal investigator 1 Amgen Inc. $9,932.12 06/23/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1246645307
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,870.00 06/19/2025 Non-covered Recipient Entity
NEXT EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235972571
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 06/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235972575
Principal investigator 1 BeOne Medicines Ltd. $9,158.00 06/17/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190331097
Principal investigator 1 BeOne Medicines USA, Inc. $17,916.00 06/17/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190331179
Principal investigator 1 PFIZER INC. $7,719.30 06/14/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07329640 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228774738
Principal investigator 1 BeOne Medicines Ltd. $1,244.00 06/10/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190326762
Principal investigator 1 Amgen Inc. $5,081.58 06/04/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 1246645072
Principal investigator 1 BeOne Medicines Ltd. $3,939.38 06/03/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190326760
Principal investigator 1 BeOne Medicines Ltd. $300.00 05/30/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190326758
Principal investigator 1 BeOne Medicines Ltd. $4,772.00 05/30/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190326764
Principal investigator 1 BeOne Medicines USA, Inc. $1,500.00 05/30/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190326722
Principal investigator 1 BeOne Medicines USA, Inc. $27,200.00 05/30/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327179
Principal investigator 1 BeOne Medicines USA, Inc. $244.00 05/30/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190330805
Principal investigator 1 BeiGene, Ltd. $35,540.00 05/20/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321248
Principal investigator 1 BeOne Medicines USA, Inc. $9,151.00 05/13/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190331177
Principal investigator 1 BeiGene, Ltd. $3,500.00 05/05/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321256
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,287.00 05/02/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES No dispute reported 06/30/2026 1184191967
Principal investigator 1 BeOne Medicines USA, Inc. $2,896.68 04/29/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190326726
Principal investigator 1 PFIZER INC. $31,000.00 04/22/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228795993
Principal investigator 1 BeOne Medicines USA, Inc. $47,414.00 04/17/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327177
Principal investigator 1 BeOne Medicines USA, Inc. $305.00 04/17/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190330803
Principal investigator 1 BeiGene, Ltd. $88,651.00 04/17/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321246
Principal investigator 1 BeiGene, Ltd. $1,270.00 04/17/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321258
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,870.00 04/09/2025 Non-covered Recipient Entity
NEXT EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235971432
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,890.00 04/09/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235971440
Principal investigator 1 BeiGene, Ltd. $635.00 04/01/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321254
Principal investigator 1 BeOne Medicines USA, Inc. $3,000.00 03/24/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190330903
Principal investigator 1 BeOne Medicines USA, Inc. $18,083.00 03/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190326208
Principal investigator 1 BeOne Medicines USA, Inc. $40,200.00 03/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190327175
Principal investigator 1 BeiGene USA, Inc. $853.47 03/11/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321240
Principal investigator 1 BeiGene, Ltd. $400.00 03/11/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190322582
Principal investigator 1 BeiGene, Ltd. $1,558.94 03/11/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190322584
Principal investigator 1 BeiGene, Ltd. $300.00 03/11/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190323380
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,410.00 03/04/2025 Non-covered Recipient Entity
NEXT EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235970778
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,410.00 03/04/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY No dispute reported 06/30/2026 1235970807
Principal investigator 1 BeiGene USA, Inc. $30,241.00 02/25/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190323426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 02/25/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES No dispute reported 06/30/2026 1184155482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $775.00 02/25/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES No dispute reported 06/30/2026 1184155484
Principal investigator 1 BeiGene, Ltd. $21,786.00 02/20/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321242
Principal investigator 1 BeiGene USA, Inc. $20,750.00 02/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321252
Principal investigator 1 BeiGene, Ltd. $305.00 02/18/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190325554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,750.00 02/13/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES No dispute reported 06/30/2026 1184153932
Principal investigator 1 BeiGene USA, Inc. $635.00 02/04/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190325558
Principal investigator 1 BeiGene, Ltd. $61.00 01/28/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190325556
Principal investigator 1 BeiGene USA, Inc. $13,845.00 01/21/2025 Non-covered Recipient Entity
NEXT Oncology
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321250
Principal investigator 1 BeiGene, Ltd. $7,868.00 01/21/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190321244
Principal investigator 1 BeiGene, Ltd. $1,500.00 01/21/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190323376
Principal investigator 1 BeiGene, Ltd. $4,479.18 01/21/2025 Non-covered Recipient Entity
NEXT Oncology
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1190323378
Principal investigator 1 Amgen Inc. $4,861.65 01/09/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 1246645320